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Abstract
Purpose Frozen gloves (FG) are effective in preventing
docetaxel-induced nail toxicity (DNT), but uncomfortable.
The preventive effect of FG for DNT was compared using a
standard (−25 to −30°C) or more comfortable (−10 to −20°C)
preparation.
Methods Breast cancer patients receiving docetaxel were
eligible. Each patient wore an FG (prepared at −10 to −20°C
for 90 min) for 60 min without replacement on the right
hand. The left hand was protected by standard methods
(FG prepared at −25 to −30°C overnight and worn for
90 min with replacement at 45 min). The primary
endpoint was DNT occurrence at 5 months. Secondary
endpoints included docetaxel exposure [cumulative dose
and area under the blood concentration time curve
(AUC)] until DNT occurrence and discomfort from
FG. The pharmacokinetics of docetaxel was assessed.
Results From 23 patients enrolled between December 2006
and June 2010, seven who received docetaxel for less than
5 months were excluded from evaluation. The median
accumulated docetaxel dose was 700 mg/m2 (340–
1430 mg/m2). Within 5 months of FG use, none developed
protocol-defined DNT in either hand. Two patients (13%)
developed DNT at 7.2 and 7.3 months, respectively, both
at −10 to −20°C. In the control hand (−25 to −30°C),
discomfort occurred in 92% of the cycles, compared to
15% in the experimental hand (−10 to −20°C). Five
patients (22%) experienced pain at −25 to −30°C, but
none did at −10 to −20°C. The degree of docetaxel
exposure was not related to DNT occurrence in our study.
Conclusion A convenient preparation of FG at −10 to −20°C
is almost as effective as a standard preparation at −25
to −30°C, with significantly less discomfort.
Keywords Chemotherapy . Docetaxel . Frozen glove . Nail
toxicity . Pharmacokinetics
Introduction
Taxanes such as docetaxel and paclitaxel have been widely
used for the treatment of various types of cancers, including
breast, lung, gynecological and gastric cancers, as palliative
chemotherapies. Since common adverse effects such as
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bone marrow and gastrointestinal toxicities have become
manageable due to the development of granulocyte colony-
stimulating factor (G-CSF) [1, 2] and 5-HT3 antagonists [3,
4], the adverse events related to cutaneous toxicities after
taxane treatment have become more important. The
important cutaneous toxicities due to taxane treatment
include hand–foot skin syndrome and nail-related adverse
events. Minisini et al. have reported that more than 40% of
patients treated with taxanes developed nail toxicities [5].
In our department, approximately 45% of patients receiving
docetaxel treatment for 4 months or longer developed
clinically significant nail toxicities (unpublished data). This
is especially relevant for breast cancer patients, who
received higher doses of taxanes than patients with other
types of cancer: more than 60% of these patients showed
clinically significant nail toxicities. Nail toxicities include
pigmentation, onychitis, onycholysis, hemorrhage and
tenderness in the nail bed. Although these adverse events
are not life threatening, they do not recover in a short
period of time and make it difficult to continue chemother-
apy, resulting in negative consequences for the patient’s
prognosis.
Scottë et al. reported that applying Elasto-Gel frozen
gloves (FG) reduced nail-related adverse events in patients
receiving docetaxel at 75 mg/m2 alone or in combination
chemotherapy [6]. They used gloves frozen at −25 to −30°C,
and 11% of patients dropped out of the study after
experiencing discomfort due to cold intolerance. In our pilot
trial, frozen gloves were also applied; however, some
patients were not able to wear them for a predetermined
period (90 min) due to discomfort (cold intolerance). Several
studies have demonstrated the usefulness of the vasocon-
strictor effect of cold stimulation on oral cavities (oral
cryotherapy) and the scalp (scalp cooling system) [7–10].
For example Ridderheim et al. reported that maintaining a
constant scalp temperature of +5°C prevented alopecia in
patients treated with anthracyclines [9]. In oral cryotherapy,
it is very unlikely that oral cavity temperatures are
maintained at 0°C or less [10]. In addition, it may be
impossible to use a −30°C freezer in some medical facilities;
therefore, the temperature of −10° to −20°C which can be
maintained by the freezer compartment of a household
refrigerator may be ideal for routine clinical use. From our
careful clinical observations of eight hospital staff volunteers,
there were no differences in the duration of the cooling effect
or in skin temperatures of the hands and fingers between
gloves frozen at −25 to −30°C and −10 to −20°C. Some
had redness and increased skin temperatures possibly
due to reactive increase in blood flow in the hand
wearing the glove frozen at −25 to −30°C. Furthermore,
seven out of eight volunteers experienced discomfort
due to cold intolerance only in the hand wearing the
glove frozen at −25 to −30°C [11].
Based on these results, we designed a study to
compare the cooling effects in each individual patient
between one control hand wearing a glove frozen for at
least overnight at −25 to −30°C, for 90 min, and the
other experimental hand wearing a glove frozen at −10
to −20°C. Considering the maximum blood concentration
time (Tmax) of docetaxel (60 min after the initiation of
dosing) [12], the patients wore a single glove on the
experimental side (the glove frozen at −10 to −20°C for
90 min) from 15 min after the initiation of docetaxel infusion
to 15 min after the end of the infusion, in order to enable a
single glove to cover the hand during the 60 min around the
time point of maximum drug concentration.
In general, each patient currently requires four gloves in
total daily (two for each hand), frozen for at least 3 h or
overnight; however, if an alternative method is available
using only two gloves in total daily (one for each hand) that
are frozen for a shorter duration (90 min, the time required
for the patient’s blood test results to become available), it
may be more practical for clinical use.
Patients and methods
Study population
Women eligible for this study were pathologically proven
stage IV or recurrent breast cancer patients who were not
candidates for curative surgery, between 20 and 69 years of
age, Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0 to 2 with adequate organ functions,
scheduled to receive docetaxel at 40 mg/m2 or more at
least once a month and who had not received more than two
doses of docetaxel on entry to the study. The criteria for
exclusion included peripheral neuropathy, edema, Ray-
naud’s symptoms or peripheral arterial ischemia which
were graded 2 or higher, the presence of suspected
metastasis in the bone, soft tissue or skin of the hands,
the presence of pleural and pericardial effusion and ascites
requiring drainage, and pre-existing nail toxicities which
were scored as equal to or higher than 5 by protocol-
defined scoring. All participants gave their written informed
consent prior to their inclusion in this study.
Study design
In this self-controlled trial, we compared the efficacy and
discomfort of FG (Elasto-Gel flexible gloves, 84400 APT
Cedex, Akromed, France) prepared using different degrees
of freezing. Patients enrolled onto this study were to receive
docetaxel over 1 h after appropriate premedication such as
dexamethasone. Some patients also received other chemo-
therapeutic agents in combination and/or zoledronic acid.
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For each patient, three frozen gloves were prepared and
used as follows. As standard protection (control), each patient
wore an FG on the left hand which was prepared at −25 to
−30°C at least overnight. These FGwere worn on the left hand
from 15 min before docetaxel administration, during the
1-h docetaxel infusion and until 15 min after the end of
infusion, a total duration of 90 min. In order to maintain the
low temperature, two gloves were used successively for
45 min each [6]. On the right hand, each patient wore an FG
prepared at −10 to −20°C for 90 min in the freezer
compartment of a household refrigerator. This was used
from 15 min after the start of docetaxel infusion until 15 min
after the end of docetaxel infusion, a total of 60 min.
This study was approved by the Ethics Committee of
Kyoto University Graduate School of Medicine (C-79) and
conducted in accordance with the Ethical Guidelines for
Clinical Studies by the Ministry of Health, Labour and
Welfare, Japan (July 30, 2003, amended December 28,
2004) and the Helsinki Declaration (1964, amended in
1975, 1983, 1989, 1996, 2000 and 2004) of the World
Medical Association. This study was registered to the
University Hospital Medical Information Network Clinical
Trials Registry (UMIN-CTR) managed by the National
University Hospital Council of Japan and operated by the
University of Tokyo Hospital (UMIN000000478).
Assessment
Nail toxicities and discomfort due to FG were assessed
and graded by the National Cancer Institute Common
Toxicity Criteria for Adverse Events (CTCAE) v3.0
before study entry and prior to every docetaxel
administration in the Outpatient Oncology Unit. Nail
toxicity was documented by photography and scored as
follows. Grade 1 nail toxicity was given 1 point for
each finger with a maximum of 5 points per hand.
Table 1 Baseline clinical characteristics of all enrolled patients and those evaluable for frozen glove efficacy
Enrolled Evaluable
n % n %
23 16
Age (years) Median 58 59
Range 40–68 44–68
<50 4 17 2 13
≥50, <60 11 48 8 50
≥60 8 35 6 38
Complications Peripheral neuropathy 1 4 1 6
Edematous hand 1 4 1 6
Raynaud’s symptoms 0 0 0 0
Peripheral arterial ischemia 0 0 0 0
Smoking history Never 20 87 13 81
Yes 2 9 2 13
Unknown 1 4 1 6
Performance status 0 23 100 16 100
Prior chemotherapy None 5 22 3 19
Yes 18 78 13 81
5-Fluoropyrimidine UFT 2 9 2 13
Doxifluridine 9 39 8 50
Capecitabine 8 35 5 31
S-1 6 26 4 25
Fluorouracil 2 9 2 13
Anthracycline Doxorubicin 1 4 0 0
Epirubicin 4 17 3 19
Taxane Paclitaxel 3 13 3 19
Vinca alkaloid Vinorelbine 1 4 1 6
Alkylating Cyclophosphamide 16 70 11 69
Others MTX, MMC, CBDCA 1 4 1 6
MTX methotrexate, MMC mitomycin C, CBDCA carboplatin
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Grade 2 nail toxicity was given 5 points for each finger.
Total points for each hand were recorded for docetaxel-
induced nail toxicity (DNT).
Pharmacokinetics
The pharmacokinetics of docetaxel was assessed within
1 month of enrollment. Blood samples were obtained
prior to docetaxel infusion, immediately before the end
of infusion and 10, 30, 60, 120 and 180 min after the
end of infusion. Drug concentration was measured by
high performance liquid chromatography with tandem
mass spectrometry. Pharmacokinetic parameters were
calculated with the software WinNonlin (Pharsight Co.,
Mountain View, CA) using the two-compartment
model.
Table 2 Treatment and pharmacokinetic results of all enrolled patients and those evaluable for frozen glove efficacy
Enrolled Evaluable
n % n %
23 16
Total docetaxel dose (mg/m2) Median 560 700
Range 80–1430 340–1430
Duration of docetaxel (months) Median 9.0 11.5
Range 0.6–24.3 5.3–24.3
<5.0 7 30 0 0
≥5.0 16 70 16 100
Combination chemotherapy No 3 13 1 6
Yes 20 87 15 94
Cytotoxic agent Cyclophosphamide 8 35 6 38
Capecitabine 1 4 0 0
Epirubicin 2 9 2 13
Hormonal agent Anastrozole 1 4 0 0
Letrozole 7 30 5 31
Exemestane 3 13 3 19
MPA 1 4 0 0
LH-RH analogue 1 4 0 0
Molecular target Trastuzumab 5 22 4 25
Pharmacokineticsa AUC (mg*h/L) Median 1.73 1.76
Range 1.14–2.78 1.14–2.78
Clearance (L/h) Median 34.7 34.6
Range 22.8–52.2 23.0–51.9
Clearance/BSA (L/h/m2) Median 22.9 22.6
Range 14.5–35.6 14.5–35.6
Cmax (mg/mL) Median 1.57 1.57
Range 0.94–2.34 0.94–2.34
Vss (L) Median 12.5 12.6
Range 6.10–36.7 8.07–36.7
a One patient whose pharmacokinetic analysis was not carried out correctly was excluded from enrolled and evaluable cohorts
AUC area under the blood concentration time curve, BSA body surface area, Cmax maximum concentration, Vss volume in steady state, MPA
medroxyprogesterone acetate, LH-RH luteinizing hormone releasing hormone





Number Event Rate (%) 95% Confidence interval
Left hand Standard:−25 to −30°C 16 0 0 0–21%
Right hand Experimental:−10 to −20°C 16 0 0 0–21%
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Statistical methodology
The primary endpoint was DNT occurrence (more than a 2-
point increase in nail toxicity scoring or any grade 2
toxicity) by 5 months. Secondary endpoints were as
follows: any grade 2 or higher DNT occurrence by
5 months, docetaxel exposure [cumulative dose and area
under the blood concentration time curve (AUC)] and time
until DNT occurrence, discomfort from FG and a detailed
description of specific DNT type.
It was estimated that the protective effect of FG on the
control hand would be 90% (DNT 10%) at 5 months. The
expected protection rate for the experimental side was 85%,
and at least higher than 50% which is the protection rate
without FG in the literature [6]. It was estimated that
analysis of 20 patients was required for a statistical power
of 80%. To be eligible for FG efficacy evaluation, patients
must have received more than five doses of docetaxel with
a total of at least 160 mg/m2 or more, over 5 months or
longer. A total enrollment of 25 patients was required for




The patients’ demographic information is listed in Table 1.
The performance status (PS) of all enrolled patients (n=23)
was 0. About 80% of patients had received chemotherapy
before enrollment, and most of these patients had received 5-
fluoropyrimidines, such as UFT, S-1 and capecitabine. The
next most common chemotherapy was cyclophosphamide in
70% of patients. Treatment information is summarized in
Table 2. The total cumulative dose of docetaxel and duration
of administration was 560 mg/m2 (80–1430 mg/m2) and
9.0 months (0.6–24.3 months). Common concurrent cyto-
toxic and hormonal agents were cyclophosphamide and
letrozole, respectively.
Efficacy of FG
Sixteen patients met the pre-specified criteria for FG
efficacy evaluation. The total cumulative dose of docetaxel
and duration of administration was 700 (340–1430)mg/m2
and 11.5 (5.3–24.3)months within the population evaluated
for FG efficacy (Table 2). None of the 16 evaluable patients
developed protocol-defined DNT before 5 months in either
hand (Table 3).
After the initial evaluation period for the primary
endpoint, two patients developed protocol-defined DNT at
7.2 and 7.3 months, respectively (Table 4). The first patient
(case #4) developed grade 2 DNT (pain with nail
pigmentation, and hemorrhage in the nail bed), and the
cumulative docetaxel dose was 440 mg/m2 before
development of DNT. Administration of docetaxel was
terminated in this patient due to recurrence of DNT and
progressive disease within a few months. The second
patient (case #10) developed nail tenderness with no other
changes in the nails at a docetaxel dose of 480 mg/m2;
however, this may not be related to docetaxel since this
patient was able to receive further docetaxel doses of
880 mg/m2 (total 1360 mg/m2) without recurrence of
DNT.
Adverse events due to FG
Although none of the enrolled patients discontinued FG use
due to intolerance, 100% (95% confidential interval 85–
Table 5 Adverse events due to
use of frozen gloves (FG) in all
enrolled patients: any discomfort
due to FG at 5 months—by
patient and by cycle
By patient N Events Rate (%) 95% CI
Left hand Standard: −25 to −30°C 23 23 100 85–100%
Right hand Experimental: −10 to −20°C 23 12 52 30–73%
By cycle Cycles Events Rate (%) 95% CI
Left hand Standard: −25 to −30°C 146 135 92 87–96%
Right hand Experimental: −10 to −15°C 146 22 15 10–22%
Table 4 Secondary endpoint: docetaxel exposure and duration before occurrence of protocol-defined DNT
Case ID Hand Duration until DNT
occurrence (days)







4 Right 222 440 640 307 Pigmentation, hemorrhage, pain
10 Right 220 480 1360 585 Tenderness
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100%) and 52% (95% confidential interval 30–73%) of
patients complained of discomfort at least once in their left
(−25 to −30°C) and right (−10 to −20°C) hands, respec-
tively, by 5 months of FG use (p<0.001 by McNemer test;
Table 5). When these results were analyzed by treatment
cycle, the values were 92% (95% confidential interval 87–
96%) and 15% (95% confidential interval 10–22%),
respectively (p<0.001 by permutation test; Table 5). Spe-
cific adverse events observed were pain (five patients=
22%, all events in the left hand), sensory neuropathy (one
event in the right hand, one event in the left, each in a
different patient) and arthritis (one patient in the right hand)
(Table 6).
Pharmacokinetic correlation
The AUC (n=22) of docetaxel (at 40 mg/m2) was 1.73
(1.14–2.78)mg*h/L for all enrolled patients except one
whose pharmacokinetic analysis was not carried out
correctly (Table 2). For patients evaluable for FG efficacy,
the total cumulative dose of docetaxel (n=16) was 700
(340–1430)mg/m2, and the AUC (n=15) was 1.76 (1.14–
2.78)mg*h/L (Table 2). Clearance (CL, n=15) and CL
adjusted by body surface area (n=15) was 34.6 (23.0–51.9)
L/h and 22.6 (14.5–35.6)L/h/m2 for those evaluable
patients (Table 2), which seems to be slightly lower than
figures reported for the Western population [13].
The AUC of case #4, who developed DNT at day 222,
was 1.71 mg*h/L, which was comparable to the median
(1.76 mg*h/L) and mean (1.78 mg*h/L) AUC. She had
received only 440 mg/m2 of docetaxel before DNT
occurrence. The AUC of case #10 was 1.14 mg*h/L. She
had received 480 mg/m2 of docetaxel before DNT. On the
other hand, none of the four patients whose AUC and total
dose were both higher than the median (1.76 mg*h/L and
560 mg/m2, respectively), out of the 15 patients evaluable
for both FG efficacy and pharmacokinetics, developed
protocol-defined DNT (Figs. 1 and 2).
Fig. 2 Area under the blood concentration time curve (AUC) for
docetaxel administered at 40 mg/m2 was plotted for patients who met
the evaluation criteria for frozen glove efficacy and pharmacokinetics.
Straight lines and broken lines indicate mean and median values,
respectively. Open circles represent data from patients who developed
DNT and closed circles from patients without DNT. This figure was
created using the Microsoft Office Powerpoint and JMP program.
AUCinf area under the blood concentration time curve extrapolated to
infinity
Fig. 1 Total docetaxel dose before development of docetaxel-induced
nail toxicity (DNT) or study closure was plotted for patients who met
the evaluation criteria for frozen glove efficacy and pharmacokinetics.
Straight lines and broken lines indicate mean and median values,
respectively. Open circles represent data from patients who developed
DNT and closed circles from patients without DNT. This figure was
created using the Microsoft Office Powerpoint and JMP program
Table 6 Other adverse events due to FG
Worst grade
n=23 0 1 2 3 4 ≥ Grade 1 (%)
Allergic reaction Left hand (standard: −25 to −30°C) 23 0 0 0 0 0
Right hand (experimental: −10 to −15°C) 23 0 0 0 0 0
Pain Left hand (standard: −25 to −30°C) 18 5 0 0 0 22
Right hand (experimental: −10 to −15°C) 23 0 0 0 0 0
Sensory neuropathy Left hand (standard: −25 to −30°C) 22 1 0 0 0 4
Right hand (experimental: −10 to −15°C) 22 1 0 0 0 4
Arthritis Left hand (standard: −25 to −30°C) 23 0 0 0 0 0
Right hand (experimental: −10 to −15°C) 22 0 1 0 0 4
2022 Support Care Cancer (2012) 20:2017–2024
Discussion
This study compared the effectiveness of FG prepared in
two different ways and used on the right and left hand in
the same patient. The standard application of FG was quite
effective for DNT prevention but caused significant
discomfort similar to that reported in the literature [6]. On
the other hand, the more convenient method including
preparation for a shorter time at higher temperature as well
as a shorter duration of application without FG replacement
was not only as effective as the standard method but also
caused less discomfort and was economically beneficial.
The occurrence of DNT seems not to be predictable from
simple docetaxel exposure.
This self-controlled study was neither blinded nor
randomized, but comparison of the right and left hand in
the same patient gives less bias relative to historical control
comparisons. It is also unknown whether our findings can
be applied to other taxane agents such as paclitaxel,
including albumin-bound paclitaxel.
Another possible weakness of this study was the
relatively lower starting dose of docetaxel (40 mg/m2)
because the study protocol allowed for combination
chemotherapy. In fact, 50% of patients received combina-
tions such as cyclophosphamide and epirubicin. The study
protocol also allowed for dose escalation depending on the
pharmacokinetic results as well as clinical toxicity and
efficacy according to the judgment of the treating physi-
cian. Median time to treatment failure in our study was 9.0
(0.6–24.2)months, and this is comparable to the time to
treatment failure of modern chemotherapy regimens such as
the docetaxel plus bevacizumab combination (8 months)
[14]. In the trial reported by Scottë et al. the cumulative
dose of docetaxel was 810 (150–1275)mg/m2, and FG
reduced the CTCAE G2 nail toxicity from 20% to zero [6].
In a study of a Japanese patient population who received a
300-mg/m2 or higher dose of docetaxel, the incidence of
CTCAE G2 nail toxicity was 14% (without protection in a
historical control) versus 4.4% (FG protected) [15]. The
cumulative and lowest total docetaxel dose in our study is
similar to those in the two studies cited previously.
Furthermore, our study suggests that the degree of
docetaxel exposure might not be an important causative
factor for DNT occurrence.
FG are usually dried overnight after use and then frozen
overnight or longer, which requires each institution to keep
at least 80 FG for ten docetaxel-treated patients per day.
The commercial cost of FG in Japan is ¥28, 000 per
glove. It is also necessary to have a special freezer at
−25 to −30°C to prepare FG. Since the cost of FG is
not covered by health care insurance in Japan, a limited
number of institutions use FG for patients who receive
docetaxel. On the other hand, the method used in this
study requires only two FG for each patient and
requires only 90-min preparation, which means that 20
FG is enough to treat ten docetaxel-treated patients per
day. It is also unnecessary to have a special freezer,
since the freezer compartment of a household refriger-
ator is enough to maintain the temperature at −10 to
−20°C. This method is therefore economically highly
beneficial. In addition, the more convenient method
used in this study is not only as effective as the
standard method but causes less discomfort.
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